Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Rhea-AI Summary

Revolution Medicines (RVMD) announced 11 presentations at the upcoming 2025 AACR Annual Meeting in Chicago (April 25-30, 2025). The highlight will be the first clinical data presentation of zoldonrasib, their RAS(ON) G12D-selective inhibitor, in non-small cell lung cancer patients during a late-breaking oral session.

Key presentations include preliminary safety and antitumor activity data of zoldonrasib in KRAS G12D NSCLC patients, the discovery of RMC-5127 (a RAS(ON) G12V-selective inhibitor), and clinical activity data of daraxonrasib in RAS mutant NSCLC. Additional presentations will cover resistance mechanisms, combination therapies, and immune response in various cancer types including pancreatic and colorectal cancers.

Positive

• First clinical data reveal of zoldonrasib in NSCLC patients at a prestigious late-breaking session
• Broad pipeline demonstration with multiple drug candidates (zoldonrasib, RMC-5127, daraxonrasib, RMC-7977)
• Strong scientific presence with 11 presentations at major cancer conference

Negative

• None.

REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced 11 oral and poster presentations will be featured at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, held from April 25 – 30, 2025.

The first clinical data in non-small cell lung cancer from the Phase 1 study of zoldonrasib, a RAS(ON) G12D-selective inhibitor, will be featured in a late breaking oral presentation.

Details of the abstracts are listed below:

Revolution Medicines Oral Presentations:

Title:	Preliminary safety and antitumor activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D non-small cell lung cancer (NSCLC) from a Phase 1 study in advanced solid tumors
Presenter:	Kathryn Arbour, M.D., Memorial Sloan Kettering Cancer Center
Abstract Number:	CT019
Session:	New Frontiers in Precision Oncology
Date/Time:	April 27; 5:00 p.m. – 5:15 p.m. CST

Title:	Discovery of RMC-5127, an oral, RAS(ON) G12V-selective, noncovalent, tri-complex inhibitor
Presenter:	Anne Edwards, Ph.D.
Abstract Number:	ND06
Session:	New Drugs on the Horizon: Part 2
Date/Time:	April 27; 3:25 p.m. – 3:40 p.m. CST

Revolution Medicines Poster Presentations:

Title:	Early reduction in circulating tumor DNA (ctDNA) is associated with clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC)
Presenter:	Jia Luo, M.D., Dana-Farber Cancer Institute
Abstract Number:	LB218
Session:	Late-Breaking Research: Clinical Research 1
Date/Time:	April 28; 2:00 p.m. – 5:00 p.m. CST

Title:	Mechanisms of resistance to the RAS(ON) multi-selective inhibitor daraxonrasib (RMC-6236) in RAS mutant PDAC and potential resolution with RAS(ON) combination therapies
Presenter:	Mallika Singh, Ph.D.
Abstract Number:	LB281
Session:	Late-Breaking Research: Experimental and Molecular Therapeutics 3
Date/Time:	April 29; 9:00 a.m. – 12:00 p.m. CST

Title:	Combination of RAS(ON) mutant-selective and multi-selective inhibitors sensitizes immune-refractory, RAS-driven preclinical models to immunotherapy
Presenter:	Mariela Moreno Ayala, Ph.D.
Abstract Number:	6046
Session:	Adaptive Immunity in Tumors / Oncogenic Pathway-Mediated Regulation of Inflammation and Tumor Immunity
Date/Time:	April 29; 2:00 p.m. – 5:00 p.m. CST

Collaborator Presentations

Title:	Distinct regulation of Cyclin D mediates heterogenous response to RAS inhibition in colorectal cancer models
Presenter:	Philip Choi, M.D., Ph.D., Memorial Sloan Kettering Cancer Center
Abstract Number:	LB293
Session:	Late-Breaking Research: Experimental and Molecular Therapeutics 3
Date/Time:	April 29; 9:00 a.m. – 12:00 p.m. CST

Title:	Combining RAS(ON) G12C-selective and RAS(ON) multi-selective inhibitors overcomes sotorasib resistance driven by KRAS G12C amplification or NRAS G13R mutation
Presenter:	Hitendra Singh Solanki, Ph.D., Moffitt Cancer Center
Abstract Number:	5512
Session:	Drug Resistance in Molecular Targeted Therapies 3
Date/Time:	April 29; 2:00 p.m. – 5:00 p.m. CST

Title:	A RAS(ON) multi-selective inhibitor combination therapy triggers long-term tumor control through senescence-associated tumor-immune equilibrium in preclinical models of PDAC
Presenter:	Caroline Broderick, Ph.D., Memorial Sloan Kettering Cancer Center
Abstract Number:	5336
Session:	CDK Inhibitors
Date/Time:	April 29; 2:00 p.m. – 5:00 p.m. CST

Title:	Preclinical evaluation of RMC-7977, a multi-selective RAS(ON) inhibitor, as a therapeutic strategy for KRAS-mutant cholangiocarcinoma
Presenter:	Jingjing Jiang, Ph.D.
Abstract Number:	5691
Session:	Oncogenes, Tumor Suppressor Genes, and Gene Products as Targets for Therapy 2
Date/Time:	April 29; 2:00 p.m. – 5:00 p.m. CST

Title:	Mechanisms of resistance to RAS-GTP inhibition in pancreatic cancer
Presenter:	Joshua H. Choe, Dana-Farber Cancer Institute
Abstract Number:	5507
Session:	Drug Resistance in Molecular Targeted Therapies 3
Date/Time:	April 29; 2:00 p.m. – 5:00 p.m. CST

Title:	T-cell dependency of tumor regressions and complete responses with RAS(ON) multi-selective inhibition in preclinical models of PDAC
Presenter:	Margo I. Orlen, Penn Medicine
Abstract Number:	6405
Session:	Checkpoints and Modulators of Tumor Microenvironment
Date/Time:	April 29; 3:25 p.m. – 3:40 p.m. CST

About Revolution Medicines, Inc.
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are currently in clinical development. The company anticipates that RMC-5127, a RAS(ON) G12V-selective inhibitor, will be its next RAS(ON) inhibitor to enter clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn.

Revolution Medicines Media & Investor Contact:
media@revmed.com
investors@revmed.com

FAQ

What is the key clinical data being presented for RVMD's zoldonrasib at AACR 2025?

The first clinical data showing preliminary safety and antitumor activity of zoldonrasib in KRAS G12D non-small cell lung cancer patients will be presented in a late-breaking oral session on April 27, 2025.

How many presentations will Revolution Medicines (RVMD) deliver at AACR 2025?

Revolution Medicines will deliver 11 oral and poster presentations at the 2025 AACR Annual Meeting in Chicago.

What are the key drug candidates RVMD is presenting data on at AACR 2025?

Key drug candidates include zoldonrasib (RMC-9805), RMC-5127, daraxonrasib (RMC-6236), and RMC-7977, targeting various RAS mutations in cancer.

What types of cancers are being targeted in RVMD's AACR 2025 presentations?

The presentations cover multiple cancer types including non-small cell lung cancer (NSCLC), pancreatic cancer (PDAC), colorectal cancer, and cholangiocarcinoma.